{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=11", "query": { "intervention": "Carbohydrate 50%", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 732, "total_pages": 74, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T19:10:45.780Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02835794", "title": "A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Omacetaxine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-08", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2017-05-03", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02835794" }, { "nct_id": "NCT00693719", "title": "Irinotecan and Etoposide in Treating Patients With Recurrent, Locally Advanced, or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Etoposide", "type": "DRUG" }, { "name": "Irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 31, "start_date": "2007-08", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693719" }, { "nct_id": "NCT00074139", "title": "Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "FEMALE", "summary": "18 Years to 69 Years · Female only" }, "enrollment_count": 0, "start_date": "2003-09", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074139" }, { "nct_id": "NCT03545867", "title": "Energetic Response to Feeding and Exercise in SCI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Spinal Cord Injuries" ], "interventions": [ { "name": "Seated control (CON)", "type": "BEHAVIORAL" }, { "name": "Moderate intensity continuous (MICT)", "type": "BEHAVIORAL" }, { "name": "High intensity interval training (HIIT)", "type": "BEHAVIORAL" }, { "name": "Circuit resistance training (CRT)", "type": "BEHAVIORAL" }, { "name": "Liquid Meal", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2018-02-28", "completion_date": "2018-09-30", "has_results": false, "last_update_posted_date": "2020-06-19", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03545867" }, { "nct_id": "NCT00899847", "title": "Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplantation, Homologous", "Transplantation, Autologous", "Multiple Myeloma", "Blood and Marrow Transplant (BMT)" ], "interventions": [ { "name": "Autologous peripheral blood stem cells (auto-PBSC) transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic peripheral blood stem cells (allo-PBSC) transplantation", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Total lymphoid irradiation", "type": "RADIATION" }, { "name": "Rabbit anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "Mycophenolate Mofetil 250mg", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 9, "start_date": "2009-05", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899847" }, { "nct_id": "NCT00581776", "title": "Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-05", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00581776" }, { "nct_id": "NCT01555489", "title": "Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2011-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01555489" }, { "nct_id": "NCT01010217", "title": "Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Blood Stem Cell Transplant Failure", "Leukemia", "Hematologic Malignancies" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycofenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 176, "start_date": "2009-11-05", "completion_date": "2017-10-05", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01010217" }, { "nct_id": "NCT02702960", "title": "Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fibrolamellar Hepatocellular Carcinoma", "Hepatocellular Carcinoma (Fibrolamellar Variant)", "Hepatocellular Carcinoma" ], "interventions": [ { "name": "living related donor partial liver transplantation", "type": "PROCEDURE" }, { "name": "Total body irradiation", "type": "RADIATION" }, { "name": "Bone marrow transplant from same donor", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "16 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2018-01-03", "has_results": false, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02702960" }, { "nct_id": "NCT03274492", "title": "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vincristine Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1000, "start_date": "2017-11-16", "completion_date": "2026-04-30", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-14T19:10:45.780Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Duarte, California + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03274492" } ] }